Drug Release from Resorbable pH-Sensitive Nanocomposites
Stanford Reference: 17-308
Executive Summary:
General Description: An electroresponsive drug delivery system that incorporates non-toxic, biodegradable FDA approved nanomaterials. Applying weak electric stimuli (0.5-1.5 V, 50-400 uA) to the nanocomposites can control the timing and quantity of drug release. This system demonstrated relatively high drug loading (>30%) and can release of both small molecules (molecular weight <500 amu) and macromolecules (molecular weights >3000 amu), hydrophilc as well as hydrophobic compounds. The conductive composition and the method of electric field-induced compound release is essential for programmed drug delivery.
Scientific Progress:
Future Directions:
Strengths:
Weaknesses:
Patent Status: Pending
Publication PMID: 29058737
Publications:
Inventor Bio: Richard N. Zare
https://web.stanford.edu/group/Zarelab
Executive Summary:
- Invention Type: Devices/Drug Delivery
- Patent Status: Pending
- Patent Link: http://techfinder.stanford.edu/technology_detail.php?ID=42155
- Research Institute: Stanford University
- Disease Focus: Diabetes
- Basis of Invention: Combination of conductive biodegradable materials and electric field for controlled drug release
- How it works: The composition comprises a conductive polymer nanoparticle, which can encapsulate an electrically-charged compound. Applying an electric field can lead to controllable release of the compound.
- Lead Challenge Inventor: Richard N. Zare
- Inventors: Richard N. Zare , Katy Margulis, Rohan Mehrotra, Devleena Samanta
- Development Stage: Pre-clinical
- Novelty:
- The method of delivering a composition
- Controllable release of drugs
- Clinical Applications:
- Chronic diseases
- Programmed drug delivery
General Description: An electroresponsive drug delivery system that incorporates non-toxic, biodegradable FDA approved nanomaterials. Applying weak electric stimuli (0.5-1.5 V, 50-400 uA) to the nanocomposites can control the timing and quantity of drug release. This system demonstrated relatively high drug loading (>30%) and can release of both small molecules (molecular weight <500 amu) and macromolecules (molecular weights >3000 amu), hydrophilc as well as hydrophobic compounds. The conductive composition and the method of electric field-induced compound release is essential for programmed drug delivery.
Scientific Progress:
- Validation of in vitro release of drugs by the system
Future Directions:
- Validation in other animal models and clinical validation
Strengths:
- This drug delivery system could be coupled to bioresorbable electronics in the future for treatment of chronic diseases like cancer, neurological disorders, and chronic pain, each of which requires repeated drug doses
Weaknesses:
- Need to be tested in animal models for reproducible results
Patent Status: Pending
Publication PMID: 29058737
Publications:
- Samanta, Devleena, Rohan Mehrotra, Katy Margulis, and Richard N. Zare. "On-demand electrically controlled drug release from resorbable nanocomposite films." Nanoscale 9, no. 42 (2017): 16429-16436.
Inventor Bio: Richard N. Zare
https://web.stanford.edu/group/Zarelab
